Rhea-AI Summary
City Therapeutics (CTY) priced its upsized initial public offering at $18.00 per share, with all shares being offered by the company. The offering comprises 11,111,111 common shares and is expected to generate approximately $200.0 million in gross proceeds before underwriting discounts, commissions and estimated offering expenses.
Underwriters received a 30-day option to purchase up to an additional 1,666,666 shares at the offering price, less underwriting discounts and commissions. Trading on the Nasdaq Global Market is expected to begin October 16, 2026. The offering is expected to close October 19, 2026, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags